1) contrast medium
造影剂，对比剂
2) contrast agent dose
造影剂剂量
1.
Objective To evaluate the feasibility of reducing the contrast agent dose for renal artery MR angiography through changing K-space filling approach.
目的探索通过改变K空间填充方式来降低肾动脉MR扫描顺磁性造影剂剂量的可行性。
3) contrast agent
造影剂
1.
The clinical research advances of liver-specific MR imaging contrast agent Mn-DPDP;
肝脏MRI造影剂Mn-DPDP临床应用研究进展
2.
The preparation of barium sulfate contrast agent used in CT;
CT用硫酸钡造影剂的制备
3.
Experimental study on MRI targeting contrast agent for rat breast cancer
大鼠乳腺癌MRI靶向造影剂的实验研究
4) contrast media
造影剂
1.
Nephrotoxicity of high-and low-osmolar contrast media: Protective role of forsinopril or telmisartan in a rat model;
高渗和低渗造影剂对鼠的肾毒性及福辛普利或替米沙坦的保护作用
2.
The role of caspase-3 in the apoptosis of glomerular endothelial cells induced by contrast media;
造影剂诱导肾小球内皮细胞凋亡的caspase-3机制
3.
Effect of high osmolar and low osmolar contrast media on function of rat renal artery endothelium in vitro;
高渗和低渗造影剂对大鼠肾动脉内皮功能的影响及意义
5) contrast agents
造影剂
1.
Progress in targeting MRI contrast agents;
靶向性磁共振成像造影剂的研究进展
2.
The applications of magnetic liposomes in magnetic separation, targeted drugs, hyperthermia, tissue engineering and contrast agents are briefly described.
综述了纳米磁性粒子和磁性脂质体的制备方法,同时简要介绍了磁性脂质体在磁性分离、靶向药物、热疗、组织工程和造影剂等领域的应用进展。
3.
Liver MR contrast agents generallycan be classified into 4 major groups based on their biodistribution within the liver.
肝脏MR造影剂分为 4大类:(1)分布于细胞外间降或间质间隙的,如Gd DTPA;(2)分布于网状内皮细胞系统或巨噬细胞 单核细胞吞噬细胞系统的,如SPIO;(3)肝细胞选择性的,如Mn-DPDP,Gd—BOPTA,Gd-EOB-DTPA;(4)血管内或血池性MR造影剂,如USPIO,AMI-227。
6) contrast agents(CA)
造影剂(CA)
补充资料：造影剂
造影剂
contrast medium
能增加组织间密度差别的物质，有阳性造影剂和负性造影剂。前者包括硫酸钡、碘油、泛影葡胺等碘制剂类造影剂，后者有空气、二氧化碳、氧气。利用造影剂引入受检的器官内或其周围，使受检部位产生密度差别。常用的造影检查部位有胃肠道、支气管、泌尿道、胆道、心血管、脑室。造影剂的引入途径有口服、灌肠、直接注入及静脉注射等。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条